ArQule (ARQL)

PRECLINICAL AND RESEARCH PIPELINE

        We have a number of pre-clinical and research-stage programs based on product candidates directed toward molecular targets that we believe play critical roles in the development of human cancers and therefore may be attractive points for therapeutic intervention. The targets, mechanisms of action and chemistry related to compounds generated from these programs differ, offering the potential for multiple therapeutic opportunities. Such intervention may be designed to activate or to inhibit targeted molecules and cell signaling pathways, depending on their roles in biological processes related to cancer.

        The targets of our most advanced research programs include the Eg5 kinesin spindle protein and the B-RAF Kinase. We have identified a candidate from our Eg5 program for which we plan to begin GLP toxicology testing in 2008. Pending the successful completion of such testing, we plan to file an Investigational New Drug application (IND) for this compound in late 2008.

PRECLINICAL AND RESEARCH PIPELINE

        We have a number of pre-clinical and research-stage programs based on product candidates directed toward molecular targets that we believe play
critical roles in the development of human cancers and therefore may be attractive points for therapeutic intervention. The targets, mechanisms of action and chemistry related to compounds generated
from these programs differ, offering the potential for multiple therapeutic opportunities. Such intervention may be designed to
activate or to inhibit targeted molecules and cell signaling pathways, depending on their roles in biological processes related to cancer.

        The
targets of our most advanced research programs include the Eg5 kinesin spindle protein and the B-RAF Kinase. We have identified a candidate from our Eg5 program for which
we plan to begin GLP toxicology testing in 2008. Pending the successful completion of such testing, we plan to file an Investigational New Drug application (IND) for this compound in late 2008.

PRECLINICAL AND RESEARCH PIPELINE

We have a number of additional pre-clinical and research-stage programs based on product candidates directed toward molecular targets that we believe play critical roles in the development of human cancers and therefore may be attractive points for therapeutic interventions. The targets, mechanisms of action and chemistry related to compounds generated from these programs differ, offering the potential for multiple therapeutic opportunities. Such intervention may be designed to activate or to inhibit targeted molecules and cell signaling pathways, depending on their roles in biological processes related to cancer. We are pursuing earlier stage research programs directed toward these targets, which include B-RAF Kinase, HSP90, HDAC and Eg5.